BC
TSVT

Barrett & Company’s 2seventy bio TSVT Stock Holding History

Barrett & Company’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-66
Closed -$353 – 625
2024
Q1 		$353 Hold
66
– – ﹤0.01% 599
2023
Q4 		$282 Hold
66
– – ﹤0.01% 596
2023
Q3 		$259 Hold
66
– – ﹤0.01% 611
2023
Q2 		$668 Hold
66
– – ﹤0.01% 576
2023
Q1 		$673 Hold
66
– – ﹤0.01% 560
2022
Q4 		$618 Hold
66
– – ﹤0.01% 565
2022
Q3 		$618 Buy
+66
New +$980 ﹤0.01% 565

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Barrett & Company's TSVT Position: Q2 2024 in Review

Barrett & Company sold out of 2seventy bio (TSVT) in Q2 2024, closing a stake of 66 shares — an estimated $353 sold.

Barrett & Company first reported a position in TSVT in Q3 2022 and held it in 7 quarters. The position peaked at $673 in Q1 2023. 115 funds tracked by Wall St. Rank hold TSVT as of Q2 2024.

  • Barrett & Company reported no remaining 2seventy bio position as of Q2 2024 after selling out during the quarter.
  • Barrett & Company sold 66 2seventy bio shares in Q2 2024, an estimated $353.
  • Barrett & Company first reported a position in 2seventy bio in Q3 2022 and held it in 7 quarters.
  • Barrett & Company's 2seventy bio position peaked at $673 in Q1 2023.
  • 115 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2024.

Based on Barrett & Company's 13F filing for Q2 2024, filed 25 Jul 2024.